Empowered lives.
Resilient nations.

TRANSPARENCY FOR INNOVATION AND ACCESS TO MEDICINES

Tenu Avafia

HIV, Health and Development Group, UNDP

Geneva, May 23 2017

Sustainable Development Goal 3

Empowered lives.
Resilient nations.

- In the same year that the SDGs were adopted:
  - 1.1 million people died from AIDS-related illnesses
  - 10.4 million TB infections, 1.8 million deaths
  - 1.4 million deaths from hepatitis B and C
  - Over 1.5 billion people needed preventive chemotherapy for at least 1 major NTD (lymphatic filariasis, onchocerciasis, soil-transmitted helminthiases, schistosomiasis, trachoma), but only 63% received it
  - 4 major NCDs accounted for 60% of 50 million deaths worldwide



The Establishment of the High-Level Panel

Two months after the 2030 Agenda for Sustainable Development was adopted, Secretary-General Ban Ki-Moon established the 15-member High-Level Panel on Access to Medicines

Report Released in September 2016



- Health technology innovation and access
- Intellectual property laws and access to health technologies
- New incentives for health technology R&D
- Governance, accountability and transparency

Challenges: Transparency on R&D and Pricing



- Reported costs of R&D of health technologies vary widely
- Without clear information on costs of R&D and delivery, governments can not realize fair return on public investments
- Public databases exist on pricing e.g. GPRM and V3P (Vaccine product, price and procurement web platform) & HAI databases
- Existing databases often do not reflect discounts, mark-ups, taxes and pricing arrangements between suppliers & procurers

Transparency Recommendations: R&D and Pricing

- Governments should require all manufacturers and distributors to disclose to drug regulators and procurers the costs of:
  - R&D; production; marketing and distribution
  - Any public funding received in the development of health technologies e.g. tax credits, subsidies & grants
- WHO should build on existing efforts and maintain an accessible database of prices of patented, generic and biosimilar medicines in countries where they are registered

Transparency Recommendations: Clinical trials and patent information

Empowered lives.
Resilient nations.

Governments should:

- require that data on all completed and discontinued clinical trials be made publicly available regardless of outcome (positive, negative or inconclusive)
- Establish and maintain publicly accessible databases with patent status on medicines & vaccines
- This information should be consolidated by WIPO including:
  - Standard International common names for biological products
  - International non-proprietary names for products
  - Dates of patent grant and expiry

HIGH-LEVEL PANEL ON ACCESS TO MEDICINES

Twitter: #UNSGAccessMeds

www.UNSGAccessMeds.org

Facebook:

http://www.**facebook**.com/UNSGAccess**meds**

For more information contact Tenu Avafia at:

tenu.avafia@undp.org